1. Code of Federal Regulations. Title 21—Food and drugs. Chapter I—Food and drug administration department of health and human services subchapter D—Drugs for human use. Part 314—Applications for FDA approval to market a new drug. Subpart C—Abbreviated Applications. Sec.314.94 Content and format of an abbreviated application. 2013. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=314.94 (accessed 18.04.15.).
2. Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products;Chang;AAPS J.,2013
3. EMA, 2010. European Medicine Agency, Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf (accessed 02.06.15.).
4. Assessment of value and applications of in vitro testing of topical dermatological drug products;Flynn;Pharm. Res.,1999
5. Reliability and reproducibility of vertical diffusion cells for determining release rates from semisolid dosage forms;Hauck;Pharm. Res.,2007